Rapamycin Treatment for ALS

Summary

Rapamycin Treatment for ALS is a clinical trial^[1].

Key Facts

• Rapamycin Treatment for ALS is in the country of Italy^[2].
• Rapamycin Treatment for ALS's instance of is recorded as clinical trial^[3].
• Rapamycin Treatment for ALS's start time is recorded as +2017-09-19T00:00:00Z^[4].
• Rapamycin Treatment for ALS's end time is recorded as +2019-04-19T00:00:00Z^[5].
• Rapamycin Treatment for ALS's contributor to the creative work or subject is recorded as Fondazione Salvatore Maugeri^[6].
• Rapamycin Treatment for ALS's main subject is recorded as sclerosis^[7].
• Rapamycin Treatment for ALS's main subject is recorded as motor neuron disease^[8].
• Rapamycin Treatment for ALS's main subject is recorded as amyotrophic lateral sclerosis^[9].
• Rapamycin Treatment for ALS's number of participants is recorded as {'unit': '1', 'amount': '+63'}^[10].
• Rapamycin Treatment for ALS's title is recorded as Rapamycin (Sirolimus) Treatment for Amyotrophic Lateral Sclerosis^[11].
• Rapamycin Treatment for ALS's short name is recorded as RAP-ALS^[12].
• Rapamycin Treatment for ALS's minimum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+18'}^[13].
• Rapamycin Treatment for ALS's ClinicalTrials.gov ID is recorded as NCT03359538^[14].
• Rapamycin Treatment for ALS's maximum age is recorded as {'unit': 'http://www.wikidata.org/entity/Q577', 'amount': '+75'}^[15].
• Rapamycin Treatment for ALS's research intervention is recorded as sirolimus^[16].
• Rapamycin Treatment for ALS's clinical trial phase is recorded as phase II clinical trial^[17].
• Rapamycin Treatment for ALS's study type is recorded as interventional study^[18].